Johnson & Johnson (JNJ) EBT Margin Growth (3y) (2012 - 2026)
Johnson & Johnson (JNJ) EBT Margin Growth (3y) (2012 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EBT Margin Growth (3y) (Qtr) |
| 1 |
Gsk |
96,436,181.12 Bn |
96,436,176.16 Bn |
7.76 Bn |
67.00 |
| 2 |
Eli Lilly |
1,017.30 Bn |
1,012.01 Bn |
16.22 Bn |
2,272.00 |
| 3 |
Johnson & Johnson |
579.61 Bn |
557.55 Bn |
15.96 Bn |
3,105.00 |
| 4 |
AbbVie |
402.30 Bn |
392.96 Bn |
10.78 Bn |
304.00 |
| 5 |
Merck |
294.24 Bn |
288.59 Bn |
12.09 Bn |
-4,669.00 |
| 6 |
Amgen |
191.82 Bn |
179.78 Bn |
5.87 Bn |
-3,220.00 |
| 7 |
Gilead Sciences |
155.93 Bn |
148.21 Bn |
5.52 Bn |
1,660.00 |
| 8 |
Pfizer |
149.05 Bn |
136.28 Bn |
-1.21 Bn |
-3,734.00 |
| 9 |
Bristol Myers Squibb |
116.33 Bn |
105.88 Bn |
8.07 Bn |
377.00 |
| 10 |
Novartis Ag |
112.59 Bn |
111.90 Bn |
- |
- |
| Date | Value |
|---|
| Mar 29, 2026 |
3,105.00 |
| Dec 28, 2025 |
96.00 |
| Sep 28, 2025 |
536.00 |
| Jun 29, 2025 |
189.00 |
| Mar 30, 2025 |
3,604.00 |
| Sep 29, 2024 |
-164.00 |
| Jun 30, 2024 |
-297.00 |
| Mar 31, 2024 |
-1,591.00 |
| Dec 31, 2023 |
1,523.00 |
| Oct 1, 2023 |
356.00 |
| Jul 2, 2023 |
782.00 |
| Apr 2, 2023 |
-3,762.00 |
| Jan 1, 2023 |
-107.00 |
| Oct 2, 2022 |
1,792.00 |
| Jul 3, 2022 |
-880.00 |
| Apr 3, 2022 |
414.00 |
| Oct 3, 2021 |
-524.00 |
| Jul 4, 2021 |
470.00 |
| Apr 4, 2021 |
589.00 |
| Jan 3, 2021 |
-535.00 |
